Search

Your search keyword '"Casey, Romain"' showing total 221 results
Start Over Author "Casey, Romain"
221 results on '"Casey, Romain"'

1. Big Multiple Sclerosis Data network: an international registry research network

Author

Glaser, Anna, Butzkueven, Helmut, van der Walt, Anneke, Gray, Orla, Spelman, Tim, Zhu, Chao, Trojano, Maria, Iaffaldano, Pietro, Battaglia, Mario A., Lucisano, Giuseppe, Vukusic, Sandra, Vukusic, Irena, Casey, Romain, Horakova, Dana, Drahota, Jiri, Magyari, Melinda, Joensen, Hanna, Pontieri, Luigi, Elberling, Frederik, Klyve, Pernilla, Mouresan, Elena Flavia, Forsberg, Lars, and Hillert, Jan

Published
2024
Full Text
View/download PDF

2. Multi-Sequence Learning for Multiple Sclerosis Lesion Segmentation in Spinal Cord MRI

Author

Walsh, Ricky, Gaubert, Malo, Meurée, Cédric, Hussein, Burhan Rashid, Kerbrat, Anne, Casey, Romain, Combès, Benoit, Galassi, Francesca, Goos, Gerhard, Series Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Linguraru, Marius George, editor, Dou, Qi, editor, Feragen, Aasa, editor, Giannarou, Stamatia, editor, Glocker, Ben, editor, Lekadir, Karim, editor, and Schnabel, Julia A., editor

Published
2024
Full Text
View/download PDF

3. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

Author

Rollot, Fabien, Couturier, Justine, Casey, Romain, Wiertlewski, Sandrine, Debouverie, Marc, Pelletier, Jean, De Sèze, Jérôme, Labauge, Pierre, Ruet, Aurélie, Thouvenot, Eric, Ciron, Jonathan, Berger, Eric, Gout, Olivier, Clavelou, Pierre, Stankoff, Bruno, Casez, Olivier, Bourre, Bertrand, Zephir, Hélène, Moreau, Thibault, Lebrun-Frenay, Christine, Maillart, Elisabeth, Edan, Gilles, Neau, Jean-Philippe, Montcuquet, Alexis, Cabre, Philippe, Camdessanché, Jean-Philippe, Defer, Gilles, Nasr, Haifa Ben, Maurousset, Aude, Hankiewicz, Karolina, Pottier, Corinne, Leray, Emmanuelle, Vukusic, Sandra, and Laplaud, David-Axel

Published
2022
Full Text
View/download PDF

4. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Debouverie, Marc, Le Page, Emmanuelle, Ciron, Jonathan, De Seze, Jerome, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Helene, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Laplaud, David Axel, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanche, Jean-Philippe, Maurousset, Aude, Moulin, Solène, Ben, Nasr Haifa, Boulos, Dalia Dimitri, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Rabilloud, Muriel, Subtil, Fabien, and Vukusic, Sandra

Published
2022
Full Text
View/download PDF

7. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Kerbrat, Anne, Le Page, Emmanuelle, Bigaut, Kevin, Mathey, Guillaume, Michel, Laure, Ciron, Jonathan, Ruet, Aurelie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Stankoff, Bruno, and Clavelou, Pierre

Published
2024
Full Text
View/download PDF

9. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.

Author

Jouvenot, Guillaume, Courbon, Guilhem, Lefort, Mathilde, Rollot, Fabien, Casey, Romain, Le Page, Emmanuelle, Michel, Laure, Edan, Gilles, de Seze, Jérome, Kremer, Laurent, Bigaut, Kevin, Vukusic, Sandra, Mathey, Guillaume, Ciron, Jonathan, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, and Defer, Gilles

Published
2024
Full Text
View/download PDF

10. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.

Author

Benallegue, Nail, Rollot, Fabien, Wiertlewski, Sandrine, Casey, Romain, Debouverie, Marc, Kerbrat, Anne, De Seze, Jérôme, Ciron, Jonathan, Ruet, Aurelie, Labauge, Pierre, Maillart, Elisabeth, Zephir, Helene, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, and Heinzlef, Olivier

Published
2024
Full Text
View/download PDF

11. The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers

Author

Brocard, Guillaume, primary, Casey, Romain, additional, Dufay, Nathalie, additional, Marignier, Romain, additional, Michel, Laure, additional, Hisbergues, Michael, additional, Ayrignac, Xavier, additional, Lehmann, Sylvain, additional, Thouvenot, Eric, additional, Gallot, Geraldine, additional, Collongues, Nicolas, additional, Herpe, Yves-Edouard, additional, Lebrun-Frenay, Christine, additional, Cotton, François, additional, De Sèze, Jérôme, additional, Guillemin, Francis, additional, Moreau, Thibault, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Vukusic, Sandra, additional, Zephir, Hélène, additional, and Laplaud, David, additional

Published
2023
Full Text
View/download PDF

12. Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis

Author

Roos, Izanne, Leray, Emmanuelle, Casey, Romain, Horakova, Dana, Havrdova, Eva, Izquierdo, Guillermo, Madueño, Sara Eichau, Patti, Francesco, Edan, Gilles, Debouverie, Marc, Pelletier, Jean, Ozakbas, Serkan, Amato, Maria Pia, Clavelou, Pierre, Grammond, Pierre, Boz, Cavit, Buzzard, Katherine, Skibina, Olga, Ciron, Jonathan, Gerlach, Oliver, GrandʼMaison, Francois, Lechner-Scott, Jeannette, Malpas, Charles, Butzkueven, Helmut, Vukusic, Sandra, and Kalincik, Tomas

Published
2021
Full Text
View/download PDF

13. The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics.

Author

Vukusic, Sandra, Bourre, Bertrand, Casey, Romain, Deiva, Kumaran, Guennoc, Anne-Marie, Lebrun-Frenay, Christine, Leray, Emmanuelle, Rollot, Fabien, Benyahya, Lakhdar, Girod, Catherine, Marignier, Romain, and Maillart, Elisabeth

Subjects
PREGNANCY, CHILDREN'S books, MULTIPLE sclerosis
Abstract

Background: Counseling on pregnancy is still challenging, particularly regarding the use of disease-modifying treatments (DMTs). We are lacking long-term outcomes in children exposed to DMTs. Objectives: This study aimed to set up a French pregnancy registry for women with multiple sclerosis (MS) and related disorders nested within the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort. Methods: Prospective, observational, multicentric, epidemiological study in France. Neurological visits are organized according to routine practice. Data are collected on the OFSEP minimal datasheet. Auto-questionnaires on pregnancy are completed by patients at Months 5–6 and 8 during pregnancy, and Months 3, 6, and 12 postpartum. A specific survey on analgesia is completed by anesthesiologists. Pediatric data are collected from the child's health book, where visits on Day 8, Month 9, and 24 are mandatory. Parents complete neurodevelopmental questionnaires at Year 1, Years 2 and 6. Results: The RESPONSE study started in August 2019. On 7 April 2023, 515 women were included. Baseline demographics are presented. Conclusions: RESPONSE will provide rich information on the global management of pregnancy in France and prospective data on children until the age of 6 years, exposed or not to a DMT, including data on neurodevelopment that can be compared to the general population. Study funding: EDMUS and ARSEP Foundation, Biogen, Roche. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

Author

Laplaud, David-Axel, Casey, Romain, Barbin, Laetitia, Debouverie, Marc, De Sèze, Jérôme, Brassat, David, Wiertlewski, Sandrine, Brochet, Bruno, Pelletier, Jean, Vermersch, Patrick, Edan, Gilles, Lebrun-Frenay, Christine, Clavelou, Pierre, Thouvenot, Eric, Camdessanché, Jean-Philippe, Tourbah, Ayman, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Lubetzki, Catherine, Papeix, Caroline, Berger, Eric, Heinzlef, Olivier, Debroucker, Thomas, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Magy, Laurent, Defer, Gilles, Guennoc, Anne-Marie, Maubeuge, Nicolas, Labeyrie, Céline, Patry, Ivania, Nifle, Chantal, Casez, Olivier, Michel, Laure, Rollot, Fabien, Leray, Emmanuelle, Vukusic, Sandra, Foucher, Yohann, Fontaine, B., Marignier, R., Durand-Dubief, F., Mathey, G., Le Page, E., Peaureaux-Averseng, D., Ouallet, J.C., Ruet, A., Collongues, N., Hautecoeur, P., Zephir, H., Maillard, E., Cohen, M., Derache, N., Branger, P., Ayrignac, X., Carra-Dalliere, C., Fromont, A., Chamard-Witkowski, L., Taithe, F., Moisset, X., Audoin, B., Rico-Lamy, A., Castelnovo, G., Giannesini, C., Fagniez, O., Bensa, C., Gueguen, A., Kasonde, I. Tabellah, De Vilmarest, A., Montcuquet, A., Vaillants, M., Beltran, S., Creange, A., Ayache, S., Abdellaoui, M., Pottier, C., Slesari, I., Deburghraeve, V., Neau, J.P., Servan, J., Pico, F., Henry, C., and Hankiewicz, K.

Published
2019
Full Text
View/download PDF

16. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Author

Sabathé, Camille, primary, Casey, Romain, additional, Vukusic, Sandra, additional, Leray, Emmanuelle, additional, Mathey, Guillaume, additional, De Sèze, Jérôme, additional, Ciron, Jonathan, additional, Wiertlewski, Sandrine, additional, Ruet, Aurélie, additional, Pelletier, Jean, additional, Zéphir, Hélène, additional, Michel, Laure, additional, Lebrun-Frenay, Christine, additional, Moisset, Xavier, additional, Thouvenot, Eric, additional, Camdessanché, Jean-Philippe, additional, Bakchine, Serge, additional, Stankoff, Bruno, additional, Al Khedr, Abdullatif, additional, Cabre, Philippe, additional, Maillart, Elisabeth, additional, Berger, Eric, additional, Heinzlef, Olivier, additional, Hankiewicz, Karolina, additional, Moreau, Thibault, additional, Gout, Olivier, additional, Bourre, Bertrand, additional, Wahab, Abir, additional, Labauge, Pierre, additional, Montcuquet, Alexis, additional, Defer, Gilles, additional, Maurousset, Aude, additional, Maubeuge, Nicolas, additional, Dimitri Boulos, Dalia, additional, Ben Nasr, Haïfa, additional, Nifle, Chantal, additional, Casez, Olivier, additional, Laplaud, David-Axel, additional, and Foucher, Yohann, additional

Published
2022
Full Text
View/download PDF

17. Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease

Author

Carra-Dallière, Clarisse, primary, Rollot, Fabien, additional, Deschamps, Romain, additional, Ciron, Jonathan, additional, Vukusic, Sandra, additional, Audoin, Bertrand, additional, Ruet, Aurélie, additional, Maillart, Elisabeth, additional, Papeix, Caroline, additional, Zephir, Hélène, additional, Laplaud, David, additional, Cohen, Mikael, additional, Bourre, Bertrand, additional, El-Bahi, Illiasse, additional, Labauge, Pierre, additional, Casey, Romain, additional, Ayrignac, Xavier, additional, and Marignier, Romain, additional

Published
2022
Full Text
View/download PDF

18. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Author

Roos, Izanne, Malpas, Charles, Leray, Emmanuelle, Casey, Romain, Horakova, Dana, Havrdova, Eva Kubala, Debouverie, Marc, Patti, Francesco, De Seze, Jerome, Izquierdo, Guillermo, Eichau, Sara, Edan, Gilles, Prat, Alexandre, Girard, Marc, Ozakbas, Serkan, Grammond, Pierre, Zephir, Helene, Ciron, Jonathan, Maillart, Elisabeth, Moreau, Thibault, Amato, Maria Pia, Labauge, Pierre, Alroughani, Raed, Buzzard, Katherine, Skibina, Olga, Terzi, Murat, Laplaud, David Axel, Berger, Eric, Grand'Maison, Francois, Lebrun-Frenay, Christine, Cartechini, Elisabetta, Boz, Cavit, Lechner-Scott, Jeannette, Clavelou, Pierre, Stankoff, Bruno, Prevost, Julie, Kappos, Ludwig, Pelletier, Jean, Shaygannejad, Vahid, Yamout, Bassem I, Khoury, Samia J, Gerlach, Oliver, Spitaleri, Daniele L A, Van Pesch, Vincent, Gout, Olivier, Turkoglu, Recai, Heinzlef, Olivier, Thouvenot, Eric, McCombe, Pamela Ann, Soysal, Aysun, Bourre, Bertrand, Slee, Mark, Castillo-Trivino, Tamara, Bakchine, Serge, Ampapa, Radek, Butler, Ernest Gerard, Wahab, Abir, Macdonell, Richard A, Aguera-Morales, Eduardo, Cabre, Philippe, Ben, Nasr Haifa, Van der Walt, Anneke, Laureys, Guy, Van Hijfte, Liesbeth, Ramo-Tello, Cristina M, Maubeuge, Nicolas, Hodgkinson, Suzanne, Sánchez-Menoyo, José Luis, Barnett, Michael H, Labeyrie, Celine, Vucic, Steve, Sidhom, Youssef, Gouider, Riadh, Csepany, Tunde, Sotoca, Javier, de Gans, Koen, Al-Asmi, Abdullah, Fragoso, Yara Dadalti, Vukusic, Sandra, Butzkueven, Helmut, Kalincik, Tomas, MSBase and OFSEP, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, University of Melbourne, Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), Recherche sur les services et le management en santé (RSMS), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], CHU Pontchaillou [Rennes], Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, CIC Plurithématique de Nantes, Institut National de la Santé et de la Recherche Médicale (INSERM)-Ministère des Affaires sociales et de la Santé-Direction générale de l'offre de soins (DGOS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Unité de Recherche Clinique de la Côte d’Azur (URRIS UR2CA), Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Génomique Fonctionnelle (IGF), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)

Subjects
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Fingolimod Hydrochloride, Recurrence, [SDV]Life Sciences [q-bio], Natalizumab, Humans, Female, Neurology (clinical), Immunosuppressive Agents, Research Article, Retrospective Studies
Abstract

Objectives:To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy.Methods:This was a retrospective cohort study from two large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12-months were included in the analysis. The primary study outcome was annualised relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation.Results:14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for seven therapies. Annualised rates of relapse (ARR) started to increase 2-months after natalizumab cessation (month 2-4 ARR, 95% confidence interval): 0.47, 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89), and stabilised faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01-0.29). Magnitude of disease reactivation for other therapies was low, but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were higher relapse rate in the year before cessation, female sex, younger age and higher EDSS. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95%CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80).Conclusion:The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different therapies. These results suggest that untreated intervals should be minimised after stopping anti-trafficking therapies (natalizumab and fingolimod).Classification of evidence:This study provides class III that disease reactivation occurs within months of discontinuation of multiple sclerosis disease-modifying therapies. Risk of disease activity is reduced by commencement of a subsequent therapy.

Published
2022

19. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Debouverie, Marc, Le Page, Emmanuelle, Ciron, Jonathan, De Seze, Jerome, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Helene, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Laplaud, David Axel, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, and Thouvenot, Eric

Published
2023
Full Text
View/download PDF

22. sj-docx-1-msj-10.1177_13524585221139156 – Supplemental material for Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Author

Sabathé, Camille, Casey, Romain, Vukusic, Sandra, Leray, Emmanuelle, Mathey, Guillaume, De Sèze, Jérôme, Ciron, Jonathan, Wiertlewski, Sandrine, Ruet, Aurélie, Pelletier, Jean, Zéphir, Hélène, Michel, Laure, Lebrun-Frenay, Christine, Moisset, Xavier, Thouvenot, Eric, Camdessanché, Jean-Philippe, Bakchine, Serge, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Maillart, Elisabeth, Berger, Eric, Heinzlef, Olivier, Hankiewicz, Karolina, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Montcuquet, Alexis, Defer, Gilles, Maurousset, Aude, Maubeuge, Nicolas, Dimitri Boulos, Dalia, Ben Nasr, Haïfa, Nifle, Chantal, Casez, Olivier, Laplaud, David-Axel, and Foucher, Yohann

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221139156 for Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system by Camille Sabathé, Romain Casey, Sandra Vukusic, Emmanuelle Leray, Guillaume Mathey, Jérôme De Sèze, Jonathan Ciron, Sandrine Wiertlewski, Aurélie Ruet, Jean Pelletier, Hélène Zéphir, Laure Michel, Christine Lebrun-Frenay, Xavier Moisset, Eric Thouvenot, Jean-Philippe Camdessanché, Serge Bakchine, Bruno Stankoff, Abdullatif Al Khedr, Philippe Cabre, Elisabeth Maillart, Eric Berger, Olivier Heinzlef, Karolina Hankiewicz, Thibault Moreau, Olivier Gout, Bertrand Bourre, Abir Wahab, Pierre Labauge, Alexis Montcuquet, Gilles Defer, Aude Maurousset, Nicolas Maubeuge, Dalia Dimitri Boulos, Haïfa Ben Nasr, Chantal Nifle, Olivier Casez, David-Axel Laplaud and Yohann Foucher in Multiple Sclerosis Journal

Published
2022
Full Text
View/download PDF

27. Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system

Author

Sabathe, C., Casey, Romain, Vukusic, S., Leray, Emmanuelle, Mathey, G., de Seze, J., Ciron, J., Wiertlewski, S., Ruet, A., Pelletier, J., Zephir, H., Michel, L., Lebrun-Frenay, C., Moisset, X., Thouvenot, Eric, Camdessanche, J. -P., Bakchine, Serge, Stankoff, B., Al Khedr, A., Cabre, P., Maillart, E., Berger, E., Heinzlef, O., Hankiewicz, K., Moreau, T., Gout, O., Bourre, B., Wahab, A., Labauge, Pierre, Montcuquet, A., Defer, G., Maurousset, A., Maubeuge, N., Dalia, D. Boulos, Ben Nasr, H., Nifle, C., Casez, O., Laplaud, D. -A., Foucher, yohann, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Strasbourg, CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Bordeaux (UB), Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire de Reims (CHU Reims), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, CHU de la Martinique [Fort de France], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Neurologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHI Poissy-Saint-Germain, Centre Hospitalier de Saint-Denis [Ile-de-France], Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Fondation Ophtalmologique Adolphe de Rotschild, CHU Rouen, Normandie Université (NU), CHU Henri Mondor [Créteil], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Limoges, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), INSERM CIC 0802 (INSERM - CHU de Poitiers), Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hémostase, Inflammation, Thrombose (HITH - U1176 Inserm - CHU Bicêtre), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Saclay, Hôpital Sud Francilien Corbeil Essonne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses [CH Versailles] (CeRéMAIA - Hôpital André Mignot), Centre Hospitalier de Versailles André Mignot (CHV), Laboratoire de Génétique Chromosomique [CHU de Grenoble], CHU Grenoble, Agence Nationale de la Recherche French National Research Agency (ANR) uropean Commission [ANR-10COHO-002], Fond de dotation de l'Universite de Nantes, Foundation EDMUS, ANR-10-COHO-0002,OFSEP,Observatoire Français de la Sclérose en Plaques(2010), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital de Hautepierre [Strasbourg]-Nouvel Hôpital Civil de Strasbourg, CHU Toulouse [Toulouse], Physiopathologie de la Plasticité Neuronale (Neurocentre Magendie - U1215 Inserm), Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Université de Poitiers, Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Meeting Abstract 035

Published
2021

28. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.

Author

Sabathé, Camille, Casey, Romain, Vukusic, Sandra, Leray, Emmanuelle, Mathey, Guillaume, De Sèze, Jérôme, Ciron, Jonathan, Wiertlewski, Sandrine, Ruet, Aurélie, Pelletier, Jean, Zéphir, Hélène, Michel, Laure, Lebrun-Frenay, Christine, Moisset, Xavier, Thouvenot, Eric, Camdessanché, Jean-Philippe, Bakchine, Serge, Stankoff, Bruno, Al Khedr, Abdullatif, and Cabre, Philippe

Subjects
*MULTIPLE sclerosis, *DYNAMICAL systems, *CONFIDENCE intervals, *DISEASE relapse
Abstract

Background: In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression. Objective: We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy. Methods: Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs). Results: From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09–0.22) for the waiting group and 0.40 (95% CI 0.32–0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30–0.46) and 0.44 (95% CI 0.37–0.52), respectively. Conclusions: By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease.

Author

Carra-Dallière, Clarisse, Rollot, Fabien, Deschamps, Romain, Ciron, Jonathan, Vukusic, Sandra, Audoin, Bertrand, Ruet, Aurélie, Maillart, Elisabeth, Papeix, Caroline, Zephir, Hélène, Laplaud, David, Cohen, Mikael, Bourre, Bertrand, El-Bahi, Illiasse, Labauge, Pierre, Casey, Romain, Ayrignac, Xavier, and Marignier, Romain

Subjects
PREGNANCY, CHILDBEARING age, FRENCH people, DATABASES, CONFIDENCE intervals
Abstract

Background and objective: Myelin-oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) frequently initiates during childbearing years. This study investigated the impact of pregnancy and post-partum on MOGAD activity. Methods: Retrospective analysis of clinical and demographic data from a multicenter French cohort of adult patients with MOGAD. All adult female patients who had a pregnancy after disease onset or in the year before disease onset were included. The annualized relapse rate was evaluated in patients who had a pregnancy after disease onset, to evaluate the impact of pregnancy and post-partum on MOGAD course. Results: Twenty-five informative pregnancies after disease onset were identified. No relapse was recorded during these pregnancies and only three relapses occurred during the first 3 months post-partum. The annualized relapse rate decreased from 0.67 (95% confidence interval: 0.40–1.10) during the pre-pregnancy period to 0 (95% confidence interval: 0–0.21) during pregnancy and to 0.22 (95% confidence interval: 0.09–0.53) during the first year post-partum. Among 144 female patients in their childbearing age recorded in the database, 18 (12.5%) reported their first symptoms during pregnancy or in the 12 months post-partum. Discussion: Our study suggests a marked reduction of MOGAD relapse rate during pregnancy and the post-partum period. Prospective studies on the role of pregnancy and delivery in MOGAD course are needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts

Author

Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Eva Kubala Havrdova, Alroughani, Raed, Ayuso, Guillermo Izquierdo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, Mccombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Walt, Anneke, Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele Litterio A., Vucic, Ostoja, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurelie, Seze, Jerome, Maillart, Elisabeth, Zephir, Helene, Labauge, Pierre, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanche, Jean-Philippe, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Celine, Nifle, Chantal, Laplaud, David, Koch-Henriksen, Nils, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Pfleger, Claudia Christina, Rasmussen, Peter Vestergaard, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, Magyari, Melinda, Vukusic, Sandra, Butzkueven, Helmut, and Kalincik, Tomas

Published
2021

31. Disability progression in multiple sclerosis patients using early first‐line treatments.

Author

Lefort, Mathilde, Vukusic, Sandra, Casey, Romain, Edan, Gilles, Leray, Emmanuelle, Cotton, François, De Sèze, Jérôme, Douek, Pascal, Guillemin, Francis, Laplaud, David, Lebrun‐Frenay, Christine, Pachot, Alexandre, Moreau, Thibault, Olaiz, Javier, Pelletier, Jean, Rigaud‐Bully, Claire, Stankoff, Bruno, Zephir, Hélène, Marignier, Romain, and Debouverie, Marc

Subjects
MULTIPLE sclerosis, GLATIRAMER acetate, DISABILITIES, OLDER patients, TREATMENT delay (Medicine), PEOPLE with disabilities
Abstract

Background and purpose: Therapeutic management of relapsing–remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression amongst RRMS first‐line‐treated patients. Methods: This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1 January 1996 to 31 December 2012 (N = 5279) from 10 MS expert Observatoire Français de la Sclérose en Plaques centres. The delay from treatment start to attaining an irreversible Expanded Disability Status Scale (EDSS) score of 3.0 was compared between the early group (N = 1882; treated within 12 months following MS clinical onset) and the later group using propensity score weighted Kaplan–Meier methods, overall and stratified by age. Results: Overall, the restricted mean time before reaching EDSS 3.0 from treatment start was 11 years and 2 months for patients treated within the year following MS clinical onset and 10 years and 7 months for patients treated later. Thus, early treated patients gained 7 months (95% confidence interval [CI] 4–11 months) in the time to reach EDSS 3.0 compared to patients treated later (treatment start delayed by 28 months). The difference in restricted mean time was respectively 6 months (95% CI 1–10 months) and 14 months (95% CI 4–24 months) in the ≤40 years age group and in the >40 years age group, in favour of the early group. Conclusions: Early treatment initiation resulted in a significant reduction of disability progression amongst patients with RRMS, and also amongst older patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Andersen, Johanna B, primary, Sharmin, Sifat, additional, Lefort, Mathilde, additional, Koch-Henriksen, Nils, additional, Sellebjerg, Finn, additional, Sørensen, Per Soelberg, additional, Hilt Christensen, Claudia C, additional, Rasmussen, Peter V, additional, Jensen, Michael B, additional, Frederiksen, Jette L, additional, Bramow, Stephan, additional, Mathiesen, Henrik K, additional, Schreiber, Karen I, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Alroughani, Raed, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Ozakbas, Serkan, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Terzi, Murat, additional, Grammond, Pierre, additional, Grand Maison, Francois, additional, Yamout, Bassem, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Trojano, Maria, additional, McCombe, Pamela, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Turkoglu, Recai, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Granella, Franco, additional, Shaygannejad, Vahid, additional, Prevost, Julie, additional, Skibina, Olga, additional, Solaro, Claudio, additional, Karabudak, Rana, additional, Wijmeersch, Bart V, additional, Csepany, Tunde, additional, Spitaleri, Daniele, additional, Vucic, Steve, additional, Casey, Romain, additional, Debouverie, Marc, additional, Edan, Gilles, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, Sèze, Jérôme D, additional, Maillart, Elisabeth, additional, Zephir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun, Christine, additional, Moreau, Thibault, additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Al-Khedr, Abdullatif, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanché, Jean-Philippe, additional, Marousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Leray, Emmanuelle, additional, Laplaud, David A, additional, Butzkueven, Helmut, additional, Kalincik, Tomas, additional, Vukusic, Sandra, additional, and Magyari, Melinda, additional

Published
2021
Full Text
View/download PDF

34. sj-pdf-1-msj-10.1177_1352458520980366.pdf – Supplemental material for Cumulative effects of therapies on disability in relapsing multiple sclerosis

Author

Rollot, Fabien, Casey, Romain, Leray, Emmanuelle, Debouverie, Marc, Edan, Gilles, Wiertlewski, Sandrine, Vukusic, Sandra, and David-Axel Laplaud

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-1-msj-10.1177_1352458520980366.pdf for Cumulative effects of therapies on disability in relapsing multiple sclerosis by Fabien Rollot, Romain Casey, Emmanuelle Leray, Marc Debouverie, Gilles Edan, Sandrine Wiertlewski, Sandra Vukusic and David-Axel Laplaud in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

35. sj-pdf-1-msj-10.1177_1352458520981300 – Supplemental material for Determinants of therapeutic lag in multiple sclerosis

Author

Izanne Roos, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, J William L Brown, Horakova, Dana, Havrdova, Eva Kubala, Debouverie, Marc, Trojano, Maria, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Edan, Gilles, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ciron, Jonathan, Ruet, Aurélie, Ozakbas, Serkan, Seze, Jérôme De, Louapre, Céline, Zephir, Hélène, Sá, Maria José, Sola, Patrizia, Ferraro, Diana, Labauge, Pierre, Defer, Gilles, Bergamaschi, Roberto, Lebrun-Frenay, Christine, Boz, Cavit, Cartechini, Elisabetta, Moreau, Thibault, Laplaud, David, Lechner-Scott, Jeannette, Francois Grand’Maison, Gerlach, Oliver, Terzi, Murat, Granella, Franco, Alroughani, Raed, Iuliano, Gerardo, Pesch, Vincent Van, Wijmeersch, Bart Van, Spitaleri, Daniele LA, Soysal, Aysun, Berger, Eric, Prevost, Julie, Aguera-Morales, Eduardo, McCombe, Pamela, Triviño, Tamara Castillo, Clavelou, Pierre, Pelletier, Jean, Turkoglu, Recai, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Sidhom, Youssef, Gouider, Riadh, Tunde Csepany, Bourre, Bertrand, Abdullatif Al Khedr, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Jean-Philippe Camdessanche, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Coles, Alasdair, Malpas, Charles B, Vukusic, Sandra, Butzkueven, Helmut, and Kalincik, Tomas

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-1-msj-10.1177_1352458520981300 for Determinants of therapeutic lag in multiple sclerosis by Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva Kubala Havrdova, Marc Debouverie, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Gilles Edan, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Jonathan Ciron, Aurélie Ruet, Serkan Ozakbas, Jérôme De Seze, Céline Louapre, Hélène Zephir, Maria José Sá, Patrizia Sola, Diana Ferraro, Pierre Labauge, Gilles Defer, Roberto Bergamaschi, Christine Lebrun-Frenay, Cavit Boz, Elisabetta Cartechini, Thibault Moreau, David Laplaud, Jeannette Lechner-Scott, Francois Grand’Maison, Oliver Gerlach, Murat Terzi, Franco Granella, Raed Alroughani, Gerardo Iuliano, Vincent Van Pesch, Bart Van Wijmeersch, Daniele LA Spitaleri, Aysun Soysal, Eric Berger, Julie Prevost, Eduardo Aguera-Morales, Pamela McCombe, Tamara Castillo Triviño, Pierre Clavelou, Jean Pelletier, Recai Turkoglu, Bruno Stankoff, Olivier Gout, Eric Thouvenot, Olivier Heinzlef, Youssef Sidhom, Riadh Gouider, Tunde Csepany, Bertrand Bourre, Abdullatif Al Khedr, Olivier Casez, Philippe Cabre, Alexis Montcuquet, Abir Wahab, Jean-Philippe Camdessanche, Aude Maurousset, Ivania Patry, Karolina Hankiewicz, Corinne Pottier, Nicolas Maubeuge, Céline Labeyrie, Chantal Nifle, Alasdair Coles, Charles B Malpas, Sandra Vukusic, Helmut Butzkueven and Tomas Kalincik in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

36. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V., Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D., Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A., Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, Magyari, Melinda, Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V., Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D., Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A., Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, and Magyari, Melinda

Abstract

Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening. Methods: By re-analyzing original published results from MSBase, France, and Denmark using uniform methodologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs. We gained access to copies of the individual amended databases and pooled all data. We used uniform inclusion/exclusion criteria and statistical methods with Inverse Probability Treatment Weighting. Results: The pooled analyses comprised 968 natalizumab- and 1479 fingolimod treated patients. The on-treatment natalizumab/fingolimod relapse rate ratio was 0.77 (p=0.004). The hazard ratio (HR) for a first relapse was 0.82 (p=0.030), and the HR for sustained EDSS improvement was 1.4 (p=0.009). There were modest differences between each of the original published studies and the replication study, but the conclusions of the three original studies remained unchanged: in two of them natalizumab was more effective, but in the third there was no difference between natalizumab and fingolimod. Conclusion: The results were largely invariant to the epidemiological and statistical methods but differed between the MS populations. Generally, the advantage of natalizumab was confirmed.

Published
2021

37. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis:A Subgroup Analysis From Three International Cohorts

Author

Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Havrdova, Eva Kubala, Alroughani, Raed, Izquierdo, Guillermo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand’Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Van der Walt, Anneke, Van Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, Magyari, Melinda, Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Havrdova, Eva Kubala, Alroughani, Raed, Izquierdo, Guillermo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand’Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Van der Walt, Anneke, Van Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, and Magyari, Melinda

Abstract

Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients’ sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. Results: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15–41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65–0.88); in those aged ≤ 38 years (0.64; 0.54–0.76); in those with disease duration ≤ 7 years (0.63; 0.53–0.76); in those with EDSS score < 4 (0.75; 0.64–0.88), < 6 (0.80; 0.70–0.91), and ≥ 6 (0.52; 0.31–0.86); and in patients with pre-baseline relapses (0.74; 0.64–0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36

Published
2021

38. Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts (2943)

Author

Sharmin, Sifat, primary, Lefort, Mathilde, additional, Andersen, Johanna Balslev, additional, Leray, Emmanuelle, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Alroughani, Raed, additional, Ayuso, Guillermo Izquierdo, additional, Ozakbas, Serkan, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Terzi, Murat, additional, Grammond, Pierre, additional, Grand’Maison, Francois, additional, Yamout, Bassem, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Trojano, Maria, additional, McCombe, Pamela, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Turkoglu, Recai, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Granella, Franco, additional, Prevost, Julie, additional, Maimone, Davide, additional, Skibina, Olga, additional, Buzzard, Katherine, additional, Van der Walt, Anneke, additional, Van Wijmeersch, Bart, additional, Csepany, Tunde, additional, Spitaleri, Daniele Litterio A., additional, Vucic, Ostoja (Steve), additional, Casey, Romain, additional, Debouverie, Marc, additional, Edan, Gilles, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, De Sèze, Jérôme, additional, Maillart, Elisabeth, additional, Zephir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun-Frénay, Christine, additional, Moreau, Thibault, additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Al-Khedr, Abullatif, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanché, Jean-Philippe, additional, Maurousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Laplaud, David, additional, Koch-Henriksen, Nils, additional, Sellebjerg, Finn Thorup, additional, Soerensen, Per Soelberg, additional, Pfleger, Claudia Christina, additional, Rasmussen, Peter Vestergaard, additional, Jensen, Michael Broksgaard, additional, Frederiksen, Jette Lautrup, additional, Bramow, Stephan, additional, Mathiesen, Henrik Kahr, additional, Schreiber, Karen Ingrid, additional, Magyari, Melinda, additional, Vukusic, Sandra, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional

Published
2021
Full Text
View/download PDF

39. High and low efficacy therapy in secondary progressive multiple sclerosis (2666)

Author

Roos, Izanne, primary, Leray, Emmanuelle, additional, Casey, Romain, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Izquierdo, Guillermo, additional, Madueño, Sara Eichau, additional, Patti, Francesco, additional, Edan, Gilles, additional, Debouverie, Marc, additional, Pelletier, Jean, additional, Ozakbas, Serkan, additional, Amato, Maria Pia, additional, Clavelou, Pierre, additional, Grammond, Pierre, additional, Boz, Cavit, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Ciron, Jonathan, additional, Gerlach, Oliver, additional, Grand-Maison, Francois, additional, Lechner-Scott, Jeannette, additional, Malpas, Charles, additional, Butzkueven, Helmut, additional, Vukusic, Sandra, additional, and Kalincik, Tomas, additional

Published
2021
Full Text
View/download PDF

40. Delay from treatment start to full effect of immunotherapies for multiple sclerosis (2679)

Author

Roos, Izanne, primary, Leray, Emmanuelle, additional, Frascoli, Federico, additional, Casey, Romain, additional, Brown, J William, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Trojano, Maria, additional, Patti, Francesco, additional, Izquierdo, Guillermo, additional, Madueño, Sara Eichau, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Prat, Alexandre, additional, Girard, Marc, additional, Grammond, Pierre, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Ozakbas, Serkan, additional, Bergamaschi, Roberto, additional, Sa, Maria Jose, additional, Cartechini, Elisabetta, additional, Boz, Cavit, additional, Granella, Franco, additional, Gerlach, Oliver, additional, Terzi, Murat, additional, Lechner-Scott, Jeannette, additional, Spitaleri, Daniele Litterio A., additional, Van Pesch, Vincent, additional, Soysal, Aysun, additional, Olascoaga, Javier, additional, Prevost, Julie, additional, Morales, Eduardo Aguera, additional, Slee, Mark, additional, Csepany, Tunde, additional, Turkoglu, Recai, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Van Wijmeersch, Bart, additional, McCombe, Pamela, additional, Macdonell, Richard, additional, Coles, Alasdair, additional, Malpas, Charles, additional, Butzkueven, Helmut, additional, Vukusic, Sandra, additional, and Kalincik, Tomas, additional

Published
2021
Full Text
View/download PDF

41. Breaking the clinico-radiological paradox in multiple sclerosis using machine learning

Author

Attyé, Arnaud, Cackowski, Stenzel, Tucholka, Alan, Roca, Pauline, Rubini, Pascal, Verclytte, Sebastien, Colas, Lucie, Ding, Juliette, Budzik, Jean-François, Renard, Felix, Barbier, Emmanuel L, Casey, Romain, Vukusic, Sandra, Cotton, François, [GIN] Grenoble Institut des Neurosciences (GIN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Pixyl Medical [Grenoble], Université catholique de Lille (UCL), Laboratoire d'Informatique de Grenoble (LIG), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Observatoire Français de la Sclérose En Plaques [Lyon] (OFSEP), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), and ANR-19-P3IA-0003,MIAI,MIAI @ Grenoble Alpes(2019)

Subjects
[INFO.INFO-LG]Computer Science [cs]/Machine Learning [cs.LG], [SDV]Life Sciences [q-bio], education
Abstract

International audience; MRI is central to the study of white matter lesions in multiple sclerosis (MS). To date, the distribution of MS lesions, as evaluated on FLAIR imaging, has not been linked to patients’ disability prediction. Based on an international data challenge with 1500 MS patients and ground truth 2-year Expanded Disability Status Scale (EDSS), we have proposed an adaptive machine learning framework to predict the clinical disability. Here, we report the encouraging finding that our algorithm predicts the 2-year EDSS score with an accuracy estimated to 81%, only based on a single initial FLAIR sequence, added to sex and gender information.

Published
2020

42. Identification of Therapeutic Lag in Multiple Sclerosis

Author

Alroughani, Raed, IULİANO, Gerardo, Hupperts, Raymond, LechnerScott, Jeannette, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Prevost, Julie, AgueraMorales, E, Urtaza, FJO, Türkoğlu, Recai, Sidhom, Youssef, Gouider, Riadh, Van Wijmeersch, Bart, Butzkueven, Helmut, Malpas, Charles, Vukusic, S, Kalincik, Tomas, ÖZAKBAŞ, SERKAN, Horakova, Dana, GI, Ayuso, Duquette, Pierre, ROOS, I, Leray, E, FRASCOLİ, F, Casey, Romain, Havrdova, Eva, Trojano, Maria, Madueno, SE, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Sola, Patrizia, Bergamaschi, Roberto, BOZ, CAVİT, Cartechini, E, SA, MJ, TERZİ, MURAT, GrandMaison, Francois, and Granella, Franco

Published
2020

43. Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Roos, Izanne, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, Brown, J William L, Horakova, Dana, Havrdova, Eva K, Trojano, Maria, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ozakbas, Serkan, Bergamaschi, Roberto, Sá, Maria José, Cartechini, Elisabetta, Boz, Cavit, Granella, Franco, Hupperts, Raymond, Terzi, Murat, Lechner-Scott, Jeannette, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Olascoaga, Javier, Prevost, Julie, Aguera-Morales, Eduardo, Slee, Mark, Csepany, Tunde, Turkoglu, Recai, Sidhom, Youssef, Gouider, Riadh, Van Wijmeersch, Bart, McCombe, Pamela, Macdonell, Richard, Coles, Alasdair, Malpas, Charles B, Butzkueven, Helmut, Vukusic, Sandra, Kalincik, Tomas, MSBase, OFSEP investigators, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Roos, Izanne, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, Brown, J William L, Horakova, Dana, Havrdova, Eva K, Trojano, Maria, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ozakbas, Serkan, Bergamaschi, Roberto, Sá, Maria José, Cartechini, Elisabetta, Boz, Cavit, Granella, Franco, Hupperts, Raymond, Terzi, Murat, Lechner-Scott, Jeannette, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Olascoaga, Javier, Prevost, Julie, Aguera-Morales, Eduardo, Slee, Mark, Csepany, Tunde, Turkoglu, Recai, Sidhom, Youssef, Gouider, Riadh, Van Wijmeersch, Bart, McCombe, Pamela, Macdonell, Richard, Coles, Alasdair, Malpas, Charles B, Butzkueven, Helmut, Vukusic, Sandra, Kalincik, Tomas, MSBase, and OFSEP investigators

Abstract

In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments ('therapeutic lag') on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and yearly review were included in the analysis. For analysis of disability progression, all events in the subsequent 5-year period were included. Density curves, representing incidence of relapses and 6-month confirmed progression events, were separately constructed for each sufficiently represented therapy. Monte Carlo simulations were performed to identify the first local minimum of the first derivative after treatment start; this point represented the point of stabilization of treatment effect, after the maximum treatment effect was observed. The method was developed in a discovery cohort (MSBase), and externally validated in a separate, non-overlapping cohort (OFSEP). A merged MSBase-OFSEP cohort was used for all subsequent analyses. Annualized relapse rates were compared in the time before treatment start and after the stabilization of treatment effect following commencement of each therapy. We identified 11 180 eligible treatment epochs for analysis of relapses and 4088 treatment epochs for disability progression. External validation was performed in four therapies, with no significant difference in the bootstrapped mean differences in therapeutic lag duration between registries. The duration of therapeutic lag for relapses was calculated for 10 therapies and ranged between 1

Published
2020

44. Determinants of therapeutic lag in multiple sclerosis

Author

Roos, Izanne, primary, Leray, Emmanuelle, additional, Frascoli, Federico, additional, Casey, Romain, additional, Brown, J William L, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Debouverie, Marc, additional, Trojano, Maria, additional, Patti, Francesco, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Edan, Gilles, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Grammond, Pierre, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, Ozakbas, Serkan, additional, De Seze, Jérôme, additional, Louapre, Céline, additional, Zephir, Hélène, additional, Sá, Maria José, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Bergamaschi, Roberto, additional, Lebrun-Frenay, Christine, additional, Boz, Cavit, additional, Cartechini, Elisabetta, additional, Moreau, Thibault, additional, Laplaud, David, additional, Lechner-Scott, Jeannette, additional, Grand’Maison, Francois, additional, Gerlach, Oliver, additional, Terzi, Murat, additional, Granella, Franco, additional, Alroughani, Raed, additional, Iuliano, Gerardo, additional, Van Pesch, Vincent, additional, Van Wijmeersch, Bart, additional, Spitaleri, Daniele LA, additional, Soysal, Aysun, additional, Berger, Eric, additional, Prevost, Julie, additional, Aguera-Morales, Eduardo, additional, McCombe, Pamela, additional, Castillo Triviño, Tamara, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Turkoglu, Recai, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Csepany, Tunde, additional, Bourre, Bertrand, additional, Al Khedr, Abdullatif, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanche, Jean-Philippe, additional, Maurousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Coles, Alasdair, additional, Malpas, Charles B, additional, Vukusic, Sandra, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional

Published
2021
Full Text
View/download PDF

48. Identification of Therapeutic Lag in Multiple Sclerosis (1787)

Author

Roos, Izanne, primary, Leray, Emmanuelle, additional, Frascoli, Federico, additional, Casey, Romain, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Trojano, Maria, additional, Ayuso, Guillermo Izquierdo, additional, Madueno, Sara Eichau, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Ozakbas, Serkan, additional, Grammond, Pierre, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Bergamaschi, Roberto, additional, Boz, Cavit, additional, Cartechini, Elisabetta, additional, Sa, Maria Jose, additional, Terzi, Murat, additional, Alroughani, Raed, additional, Grand’Maison, Francois, additional, Granella, Franco, additional, Iuliano, Gerardo, additional, Hupperts, Raymond, additional, Lechner-Scott, Jeannette, additional, Spitaleri, Daniele Litterio A., additional, Van Pesch, Vincent, additional, Soysal, Aysun, additional, Prevost, Julie, additional, Morales, Eduardo Aguera, additional, Urtaza, Francisco Javier Olascoaga, additional, Turkoglu, Recai, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Van Wijmeersch, Bart, additional, Butzkueven, Helmut, additional, Malpas, Charles, additional, Vukusic, Sandra, additional, and Kalincik, Tomas, additional

Published
2020
Full Text
View/download PDF

49. Determinants of Therapeutic Lag in Multiple Sclerosis (2059)

Author

Roos, Izanne, primary, Leray, Emmanuelle, additional, Frascoli, Federico, additional, Casey, Romain, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Trojano, Maria, additional, Ayuso, Guillermo Izquierdo, additional, Madueno, Sara Eichau, additional, Patti, Francesco, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Grammond, Pierre, additional, Ozakbas, Serkan, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Bergamaschi, Roberto, additional, Cartechini, Elisabetta, additional, Sa, Maria Jose, additional, Boz, Cavit, additional, Grand-Maison, Francois, additional, Lechner-Scott, Jeannette, additional, Terzi, Murat, additional, Granella, Franco, additional, Alroughani, Raed, additional, Iuliano, Gerardo, additional, Hupperts, Raymond, additional, Spitaleri, Daniele Litterio A., additional, Van Pesch, Vincent, additional, Soysal, Aysun, additional, Prevost, Julie, additional, Urtaza, Francisco Javier Olascoaga, additional, Morales, Eduardo, additional, Turkoglu, Recai, additional, Slee, Mark, additional, Ramo, Cristina, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, McCombe, Pamela, additional, Butzkueven, Helmut, additional, Malpas, Charles, additional, Vukusic, Sandra, additional, and Kalincik, Tomas, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results